Announced Fri, 15 May · 19:41 IST

Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Revenue Growth 20pctExceptional ItemResults View source PDF

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹766.00
prior close
₹748.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.2+0.3+0.2-3.4-2.3+0.5-1.0-1.6+2.4+2.0+3.1+3.3
Up moveDown movePending
AI summary

Krishna Institute of Medical Sciences reported audited consolidated results for Q4 and full year FY2026 ended March 31, 2026. Total consolidated revenue grew ~24% to Rs 16,120 million from ~Rs 12,978 million in the prior year. Profit after tax (after non-controlling interests) came in at Rs 2,000 million for the year. Auditors S.R. Batliboi & Associates LLP issued an unmodified (clean) opinion on both standalone and consolidated results. An exceptional item of Rs 74 million was recorded due to a one-time increase in employee benefit provisions from the implementation of the new Labour Codes effective November 21, 2025. The company also appointed new senior management including a CFO and re-designated Mr. Adwik Bollineni (son of the CMD and brother of the CEO) as an Executive Director.

Likely market impact

The company delivered strong revenue growth above 20% with clean audit findings, which is broadly positive for investors. However, the large exceptional item and related-party re-designation may attract scrutiny. The significant increase in borrowings (long-term debt rose to Rs 26.7bn from Rs 16.5bn) warrants monitoring.